SLU-PP-332 BAM15 Peptide Blend Research – Complete Guide

Table of Contents

• Quick Facts
• What is the SLU-PP-332 BAM15 Blend?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Obesity, metabolic syndrome, fatty liver disease, exercise physiology, cardiac function, type 2 diabetes
• Compound Classification: SLU-PP-332 is a synthetic small-molecule ERR pan-agonist; BAM15 is a selective mitochondrial uncoupler; both are frequently discussed within peptide research contexts
• Development Origin: SLU-PP-332 developed at Saint Louis University; BAM15 developed as a safer alternative to early mitochondrial uncouplers
• Key Mechanisms: SLU-PP-332 activates ERRalpha, ERRbeta, and ERRgamma; BAM15 dissipates the mitochondrial proton gradient
• Published Animal Studies: SLU-PP-332 demonstrated 70% endurance improvement and 12% body weight reduction in mouse models; BAM15 reversed diet-induced obesity and reduced hepatic fat in rodent studies
• Clinical Trial Status: No Phase II or III human trials confirmed for either compound; no peer-reviewed combination studies identified as of 2024
• WADA Status: SLU-PP-332 is banned under WADA Prohibited List Category S4; BAM15 status not confirmed on available prohibited lists
• Regulatory Classification: Both compounds are for research use only; neither is FDA-approved for human therapeutic use
• Combination Research: No peer-reviewed studies have examined this blend directly; combination rationale is based on mechanistic extrapolation from individual compound research

What is the SLU-PP-332 BAM15 Blend?

SLU-PP-332 and BAM15 are two synthetic compounds that have attracted research interest for their distinct but potentially complementary effects on energy metabolism. Neither is a classical peptide in the strict biochemical sense, though both are frequently discussed within peptide research and metabolic compound literature. Some commercial sources describe SLU-PP-332 using peptide-adjacent language, and it is routinely marketed alongside research peptides. The peer-reviewed scientific literature consistently classifies it as a synthetic small-molecule agonist, not a traditional peptide. This classification distinction matters for researchers interpreting mechanism studies and pharmacokinetic data.

SLU-PP-332 was developed at Saint Louis University as a pan-agonist of estrogen-related receptors (ERRs), a family of nuclear receptors that govern mitochondrial energy regulation. Researchers describe it as an "exercise mimetic" because it activates genetic pathways in skeletal muscle and cardiac tissue that are normally triggered by sustained aerobic activity. Animal studies published between 2022 and 2024 showed substantial improvements in endurance capacity and fat oxidation without changes in food intake or lean mass, generating significant interest in metabolic research circles.

BAM15 was developed as a structurally improved alternative to earlier mitochondrial uncouplers, most notably 2,4-dinitrophenol (DNP). DNP achieved weight loss in the early 20th century by forcing mitochondria to burn fuel without producing usable energy, but its narrow therapeutic window caused serious toxicity and deaths. BAM15 targets the same fundamental mechanism, dissipating the proton gradient across the inner mitochondrial membrane, but with a profile that avoids the hyperthermia seen with DNP in preclinical models. Rodent studies showed meaningful reductions in body fat, hepatic lipids, and insulin resistance without temperature changes or lean mass loss.

Researchers have proposed combining these two compounds because they act on different parts of the mitochondrial energy system. SLU-PP-332 remodels the cellular machinery for oxidative metabolism over time through gene regulation, while BAM15 immediately increases the rate at which fuel is consumed through direct uncoupling. No peer-reviewed studies have tested this combination directly. The rationale for pairing them comes from mechanistic reasoning and a small body of non-peer-reviewed community discussion, not controlled experimental data.

Both compounds are available only as research chemicals for laboratory use. Neither carries FDA approval for human therapeutic applications, and SLU-PP-332 is explicitly prohibited by WADA in competitive sports. The broader peptide research community can find overviews of related metabolic compounds through the Cenexa Labs peptide research library.

Molecular Structure and Core Properties

Chemical Structure and Specifications

SLU-PP-332 Technical Specifications

BAM15 Technical Specifications

Key Structural Features

SLU-PP-332 functions as a nuclear receptor ligand, binding to the ligand-binding domains of ERRalpha, ERRbeta, and ERRgamma to activate transcriptional programs governing mitochondrial biogenesis and fatty acid oxidation enzymes. Its selectivity profile shows highest potency at ERRalpha and preference for ERRalpha over ERRgamma, which researchers suggest may reduce the induction of hepatic gluconeogenesis compared to less selective ERR agonists. In vitro metabolism studies using human liver S9 fractions and microsomes identified nine metabolites, six Phase-I and three Phase-II conjugates, detected via LC-HRMS/MS methodology. These metabolite profiles are now being studied by anti-doping researchers.

BAM15 is a lipophilic small molecule designed to insert into the inner mitochondrial membrane and facilitate proton leak, collapsing the electrochemical gradient that drives ATP synthesis. This forces mitochondria to increase substrate oxidation to maintain cellular energy balance. Its lipophilicity enables effective membrane penetration but creates low aqueous solubility that complicates dosing and formulation. The short plasma half-life of approximately 1.7 hours limits sustained systemic exposure, which has driven research into nanoparticle delivery systems targeting specific organs.

A commercially available blend product called SLUBAM combines both compounds at 250 mcg SLU-PP-332 and 50 mg BAM15 per capsule, labeled strictly for laboratory and non-clinical research use only.

Mechanisms of Action Being Investigated

SLU-PP-332 and BAM15 act on mitochondrial energy metabolism through fundamentally different mechanisms that do not overlap at the molecular level. This non-overlap forms the theoretical basis for combination research interest, though no peer-reviewed studies have directly tested whether these mechanisms interact productively or competitively.

SLU-PP-332: ERR Pan-Agonism and Transcriptional Reprogramming

SLU-PP-332 binds and activates all three estrogen-related receptors, with greatest potency at ERRalpha [pmc.ncbi.nlm.nih.gov/articles/PMC10801787/]. ERRalpha functions as a master regulator of mitochondrial gene expression. When activated, it drives transcription of genes encoding fatty acid oxidation enzymes, mitochondrial respiratory chain components, and oxidative phosphorylation proteins.

The downstream effects include increased production of the mitochondrial biogenesis co-activator PGC-1alpha, upregulation of GLUT4 glucose transporters, and increased expression of uncoupling proteins involved in thermogenesis. Skeletal muscle exposed to SLU-PP-332 shifts toward a more oxidative fiber profile, increasing the proportion of type IIa fibers that sustain aerobic activity. This muscle remodeling effect is the basis for the endurance improvements seen in animal studies.

In cardiac tissue, SLU-PP-332 activation of ERR pathways improved contractility and reduced fibrosis in heart failure models, suggesting the transcriptional reprogramming extends beyond skeletal muscle to heart tissue [pmc.ncbi.nlm.nih.gov/articles/PMC10399613/]. ERRalpha preference over ERRgamma in SLU-PP-332’s selectivity profile may also limit unwanted activation of hepatic gluconeogenesis pathways that ERRgamma governs.

SLU-PP-332: Substrate Utilization Shift

A key metabolic consequence of ERR activation by SLU-PP-332 is a reduction in the respiratory exchange ratio (RER), a measure of which fuel the body burns. Lower RER values indicate greater reliance on fat oxidation relative to carbohydrate combustion. Treated mice showed a 25% increase in fatty acid oxidation compared to vehicle controls, with a reciprocal reduction in carbohydrate utilization [pmc.ncbi.nlm.nih.gov/articles/PMC10801787/]. Resting energy expenditure also increased, meaning treated animals burned more calories at rest without changes in food intake.

BAM15: Proton Gradient Dissipation and Forced Nutrient Oxidation

BAM15 works by inserting into the inner mitochondrial membrane and facilitating proton re-entry into the mitochondrial matrix, bypassing the ATP synthase enzyme. This collapses the proton gradient that drives ATP production [pmc.ncbi.nlm.nih.gov/articles/PMC7224297/]. Cells compensate by accelerating the electron transport chain and consuming more substrate to attempt to restore the gradient.

The practical effect is that mitochondria burn more fat and glucose simultaneously, increasing total nutrient oxidation without the cell needing to perform additional mechanical work. Unlike some mitochondrial uncouplers, BAM15 does not appear to cause dangerous heat generation at doses effective for metabolic improvement in mouse models. Body temperature remained stable in treated animals, distinguishing BAM15 from DNP, which caused lethal hyperthermia in some research models.

BAM15 also activates AMPK, a cellular energy sensor, in models of septic acute kidney injury, suggesting metabolic effects beyond simple nutrient burning [pubmed.ncbi.nlm.nih.gov/37900126/]. AMPK activation promotes cellular energy conservation and has its own downstream effects on fatty acid oxidation and glucose uptake.

BAM15: Calcium Efflux and Cellular Signaling

Research has shown BAM15 triggers calcium efflux from rat liver mitochondria. Calcium plays a regulatory role in mitochondrial metabolism and can influence enzyme activity within the mitochondrial matrix. The significance of this calcium efflux for the broader metabolic effects of BAM15 is not yet fully characterized.

Combination Pathway Analysis and Theoretical Synergy

The proposed rationale for combining these two compounds rests on their non-overlapping targets. SLU-PP-332 acts through nuclear receptors to gradually reshape the transcriptional landscape of cells, increasing the capacity for fat oxidation over days to weeks as gene expression changes accumulate. BAM15 acts immediately at the mitochondrial membrane to drive increased substrate consumption independent of gene regulation.

One analogy from non-peer-reviewed community discussion frames SLU-PP-332 as "priming" the mitochondria through biogenesis and fiber conversion, while BAM15 "drives" increased fuel consumption through direct uncoupling. Whether these effects are truly additive or synergistic, and whether they might compete in some cellular contexts, has not been studied directly. No peer-reviewed publication has examined their interaction.

Non-peer-reviewed sources also specifically caution against simultaneous administration, arguing that taking both at the same time may generate excessive heat and dissipate electrons in ways that negate the benefits of each compound individually. These warnings come from mechanistic reasoning and community protocols, not controlled experiments. The compounds’ respective half-lives, approximately 6 hours for SLU-PP-332 and approximately 1.7 hours for BAM15, have led some researchers to propose alternating their use rather than co-administering them.

Major Areas of Research

Research on these compounds spans several metabolic and physiological domains. Most published work examines each compound independently. Combination-specific research exists only at the community protocol level, without peer-reviewed study designs.

Obesity and Body Composition Research

Metabolic obesity research represents the most developed application area for both compounds. SLU-PP-332 studies in diet-induced obese mice used a protocol of 50 mg/kg twice daily for 28 days under thermoneutrality conditions. Animals receiving SLU-PP-332 gained ten times less fat than untreated controls and lost approximately 12% of body weight [pmc.ncbi.nlm.nih.gov/articles/PMC10801787/]. Importantly, these changes occurred without any reduction in food intake, meaning the compound altered how calories were processed rather than how many were consumed. Adipocyte size and brown adipose tissue mass remained unchanged, suggesting the fat reduction came from enhanced oxidation rather than altered adipogenesis.

BAM15 studies in diet-induced obesity mouse models showed reversal of established obesity, decreased total body fat mass, and reduced hepatic lipid accumulation [pmc.ncbi.nlm.nih.gov/articles/PMC7224297/]. The compound also reduced inflammatory lipid species and improved insulin sensitivity across multiple tissues simultaneously.

Key Research Highlights:

• SLU-PP-332: 10-fold reduction in fat gain in obese mice; 12% body weight reduction over 28 days
• BAM15: Reversal of diet-induced obesity without changes in lean mass or body temperature
• Both compounds: No appetite suppression observed, suggesting metabolic rather than behavioral mechanisms

Non-Alcoholic Fatty Liver Disease (NAFLD) Studies

Hepatic fat accumulation, a hallmark of NAFLD and metabolic syndrome, was reduced by both compounds in animal models. SLU-PP-332 alleviated hepatic steatosis in treated mice, with improvements in liver fat consistent with enhanced whole-body fatty acid oxidation [pmc.ncbi.nlm.nih.gov/articles/PMC10801787/]. BAM15 reduced hepatic fat content and demonstrated 51% higher palmitate oxidation rates specifically in liver tissue [pmc.ncbi.nlm.nih.gov/articles/PMC7224297/]. BAM15 also reduced lipid peroxidation markers by 49%, measured as 4-hydroxynonenal levels, and elevated glutathione concentrations, suggesting a reduction in oxidative stress alongside the metabolic improvements.

A targeted delivery approach using BAM15@BSA nanoparticles was developed to concentrate BAM15 effects specifically in liver tissue for NAFLD treatment, potentially allowing lower systemic doses to achieve organ-specific therapeutic outcomes [pmc.ncbi.nlm.nih.gov/articles/PMC10600450/].

Key Research Highlights:

• SLU-PP-332: Reduced hepatic steatosis in diet-induced obese mouse models
• BAM15: 51% increase in liver palmitate oxidation; significant reduction in lipid peroxidation
• BAM15 nanoparticle delivery: Liver-targeted formulation showing organ-specific NAFLD effects

Exercise Physiology and Endurance Research

SLU-PP-332’s classification as an exercise mimetic derives from its effects on skeletal muscle fiber composition and aerobic capacity. Mice treated with SLU-PP-332 ran 70% longer and covered 45% more distance than untreated controls in endurance tests [news.ufl.edu/2023/09/exercise-mimicking-drug/]. These improvements accompanied measurable shifts toward oxidative muscle fiber phenotypes, the fiber type predominant in endurance-trained athletes. In vitro studies in C2C12 myocytes confirmed enhanced respiration and upregulation of ERR target genes involved in oxidative metabolism.

The WADA ban on SLU-PP-332 reflects this potent exercise-mimicking activity. The compound’s ability to improve endurance metrics without physical training creates obvious implications for competitive athletics, which led to its placement on the prohibited list under hormone and metabolic modulators.

Key Research Highlights:

• 70% increase in running duration in treated versus untreated mice
• 45% increase in total running distance
• Oxidative muscle fiber conversion without physical training
• ERR target gene upregulation confirmed in muscle cell cultures

Cardiovascular Research Applications

Both compounds show activity in cardiac tissue. SLU-PP-332 improved contractility and reduced fibrosis in heart failure animal models through ERR-mediated transcriptional changes [pmc.ncbi.nlm.nih.gov/articles/PMC10399613/]. ERRalpha is highly expressed in heart tissue, where mitochondrial function is critical for continuous contractile performance. Reduced cardiac apoptosis was also observed in treated models.

BAM15’s effects on cardiac tissue are less extensively studied than its metabolic applications, but its AMPK-activating properties and direct effects on mitochondrial function in heart cells make cardiovascular applications a plausible area for future investigation. Research on other mitochondrial-targeted compounds such as BPC-157 has also explored cardiac protection mechanisms, illustrating the broader interest in mitochondria-targeted approaches to heart health. The BPC-157 and Organ Protection Research article provides relevant context for organ-level protective mechanisms under investigation in peptide research.

Key Research Highlights:

• SLU-PP-332: Improved cardiac contractility in heart failure models
• SLU-PP-332: Reduced fibrosis and apoptosis in cardiac tissue
• ERRalpha activation particularly relevant in high-energy-demand heart tissue

Type 2 Diabetes and Insulin Resistance Research

Insulin sensitivity improvements represent a key finding for BAM15 in animal models. Treated mice showed reduced insulin resistance across liver, skeletal muscle, and adipose tissue simultaneously [pmc.ncbi.nlm.nih.gov/articles/PMC7224297/]. This multi-tissue improvement suggests systemic rather than organ-specific effects on insulin signaling, potentially mediated through reductions in ectopic lipid accumulation and inflammatory lipid species.

SLU-PP-332 upregulates GLUT4 glucose transporters in muscle tissue, which independently supports glucose uptake independent of insulin signaling. This GLUT4 effect is one mechanism through which the ERR activation pathway may contribute to improved glycemic regulation in metabolic disease models.

Key Research Highlights:

• BAM15: Reversed insulin resistance across liver, muscle, and fat tissue simultaneously
• SLU-PP-332: Upregulated GLUT4 glucose transporters in skeletal muscle
• Both: Reduced hepatic lipid accumulation, a driver of hepatic insulin resistance

Septic Acute Kidney Injury Research

BAM15 demonstrated protective effects in models of septic acute kidney injury (AKI) through AMPK activation [pubmed.ncbi.nlm.nih.gov/37900126/]. This application is distinct from its obesity and metabolic work, expanding the research profile beyond metabolic syndrome to acute organ protection contexts. AMPK activation in kidney tissue during sepsis may help cells maintain energy balance under inflammatory stress conditions. This research area remains early-stage but illustrates that BAM15’s mechanism has potential relevance beyond weight management.

Key Research Highlights:

• BAM15 activates AMPK in early septic acute kidney injury models
• Protective effect on kidney tissue under acute inflammatory conditions
• Expands research scope beyond metabolic obesity applications

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

BAM15 is orally bioavailable, confirmed in preclinical studies. Its lipophilic structure facilitates absorption across gastrointestinal membranes despite low aqueous solubility. The primary challenge is that this same lipophilicity creates formulation difficulties when attempting to achieve consistent dosing in research settings.

SLU-PP-332 is currently administered via injection in research protocols, as oral formulations have not been validated for human use. A related compound, SLU-PP-915, has demonstrated oral bioavailability as a pan-ERR agonist with similar exercise-mimetic activity, and structural refinement of SLU-PP-332 toward oral delivery is an active research direction [pubmed.ncbi.nlm.nih.gov/41421047/].

Distribution and Metabolism

In vitro metabolism studies using human liver S9 fractions and microsomes characterized SLU-PP-332’s metabolic profile: six Phase-I oxidative metabolites and three Phase-II conjugates, detected using LC-HRMS/MS techniques [pmc.ncbi.nlm.nih.gov/articles/PMC12835572/]. These metabolites are being profiled by anti-doping researchers because WADA’s prohibition of SLU-PP-332 requires reliable detection methods in biological samples.

BAM15 has an approximate half-life of 1.7 hours based on preclinical data, which limits sustained systemic exposure. The compound distributes to lipid-rich environments consistent with its high lipophilicity. In the BAM15@BSA nanoparticle formulation, distribution was concentrated in liver tissue, demonstrating that delivery engineering can redirect the compound’s tissue distribution substantially [pmc.ncbi.nlm.nih.gov/articles/PMC10600450/].

Delivery Methods Under Investigation

• Subcutaneous injection (SLU-PP-332): Current standard for animal research studies; systemic distribution confirmed in rodent models
• Oral formulation (SLU-PP-332): Under development; structural refinement required before validation in humans
• Oral administration (BAM15): Functional in preclinical models; low aqueous solubility requires careful formulation
• BAM15@BSA nanoparticles: Novel targeted delivery system directing BAM15 to liver tissue; reduces systemic exposure while achieving organ-level effects; under investigation for NAFLD applications

Excretion and Clearance

SLU-PP-332’s nine identified metabolites undergo standard hepatic processing pathways. The approximately 6-hour half-life reported in non-peer-reviewed sources (not confirmed in peer-reviewed pharmacokinetic studies) would suggest hepatic clearance as the primary elimination route, consistent with the metabolite profile.

BAM15’s rapid clearance at approximately 1.7 hours necessitates either frequent dosing or advanced formulation for sustained biological effect. This short half-life has practical implications for any combination protocol, as BAM15 clears relatively quickly between doses, potentially reducing interaction risks if a separation window is maintained between administrations of the two compounds.

No human pharmacokinetic data exists for either compound. All absorption, distribution, metabolism, and excretion data is derived from preclinical models.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data Neither compound has published Phase II or III human clinical trial results. Some non-peer-reviewed sources suggest BAM15 has entered human safety or tolerability testing, but no ClinicalTrials.gov registrations or published results were identified in the available literature. SLU-PP-332 has no confirmed investigational new drug application or registered human trials. Safe and effective dosing in humans remains completely undefined for both compounds. Long-term effects at any dose are unknown beyond 28-day animal study protocols.

Combination Research Absence No peer-reviewed study has examined SLU-PP-332 and BAM15 together in any model. Every claim about combination effects derives from mechanistic extrapolation from individual compound research, commercial product descriptions, or community discussion in podcasts and biohacking forums. The synergy rationale is scientifically plausible given the non-overlapping pathways, but it is speculative until tested directly. Pharmacokinetic interaction data, combined toxicology, and optimal ratio information are all completely absent.

Mechanistic Understanding Gaps The significance of BAM15-induced calcium efflux from mitochondria has not been fully characterized. SLU-PP-332’s effects on ERRbeta and ERRgamma remain less studied than its ERRalpha activity. The long-term consequences of sustained ERR pathway activation, including any effects on estrogen-related hormonal signaling, have not been investigated in female-specific models. Given that ERRs share structural homology with estrogen receptors, this gap is particularly notable.

Methodological Considerations Most animal research used C57BL/6J male mice at thermoneutrality conditions, which do not fully represent human physiology, thermal regulation differences, or the diversity of metabolic disease presentations. Mouse metabolic rates differ substantially from human rates, making direct dose translation unreliable. No studies in female animals, aged animals, or models of comorbid conditions have been published.

Areas Needing Further Investigation

• Human pharmacokinetic and safety studies: fundamental prerequisite before any human application can be considered
• Female-specific models: ERR pathway relevance to estrogen-related hormonal signaling requires investigation in female subjects
• Dedicated combination study design: the synergy hypothesis requires controlled testing in animal models before any further claims can be made
• Long-term safety beyond 28 days: chronic administration effects for both compounds are unknown
• Drug-drug interaction profiles: how each compound interacts with common medications is entirely uncharacterized
• Broader animal models: species beyond C57BL/6J mice needed to assess generalizability of findings
• Validated oral formulation for SLU-PP-332: current injection requirement limits practical research applications
• BAM15 formulation improvements: addressing the 1.7-hour half-life for sustained research exposure

Regulatory and Research Status

Current Classification

FDA Status Neither SLU-PP-332 nor BAM15 holds FDA approval for any human therapeutic indication. SLU-PP-332 has not completed the multi-phase clinical trial process required for approval and has no recognized medical use in humans in the United States. It is not a DEA-controlled substance based on available information, but its sale or marketing for human consumption is not legally permitted. BAM15 carries similar research-only status without confirmed FDA regulatory actions specific to this compound. Both are available from legitimate research chemical suppliers for laboratory and non-clinical scientific use only.

Researchers considering sourcing either compound should prioritize verifiable purity standards. Research-grade specifications require greater than or equal to 98.0% purity by reversed-phase HPLC and endotoxin levels below 0.1 EU/mg. The Cenexa Pure Process outlines manufacturing and purity verification standards relevant to research compound quality.

WADA Status WADA explicitly prohibits SLU-PP-332 on its Prohibited List under Category S4: Hormone and Metabolic Modulators. The classification reflects the compound’s demonstrated performance-enhancing effects in animal studies, particularly the endurance improvements and metabolic rate elevation. Any athlete subject to WADA anti-doping testing who tests positive for SLU-PP-332 or its metabolites faces a doping violation. Anti-doping laboratories are actively developing detection methods using the nine metabolite profiles identified through LC-HRMS/MS in human liver microsomes.

BAM15 is not confirmed on available WADA prohibited lists based on current data. Researchers and athletes should independently verify current prohibited substance lists directly with WADA before drawing conclusions about BAM15’s competitive sport status.

International Perspective No specific international regulatory classifications beyond WADA’s prohibition of SLU-PP-332 were confirmed in available sources. Both compounds are treated as research chemicals across major international markets. Commercial products combining both compounds, including SLUBAM capsules from simplepeptide.com, carry explicit research-use-only and not-for-human-consumption labeling as required by applicable regulations.

Research Community Approach

Active preclinical research on SLU-PP-332 continues at university research institutions, with peer-reviewed publications appearing in journals including ACS Chemical Biology and the Journal of Pharmacology and Experimental Therapeutics. BAM15 research spans obesity pharmacology, NAFLD treatment, and acute organ protection. Both compounds require institutional ethical oversight and compliance with applicable research regulations in any legitimate laboratory setting.

The broader context of the peptide research field, including supply and quality considerations following changes in the research peptide supplier landscape, is relevant for researchers sourcing compounds. The Peptide Sciences alternative resource addresses sourcing considerations for researchers navigating research compound procurement.

Future Research Directions

SLU-PP-332 requires structural refinement for validated oral formulation before broader research applications become practical. Further animal side-effect testing across multiple species and longer durations is needed before human trials can be responsibly designed. The WADA ban introduces anti-doping detection as an active parallel research stream, which may produce pharmacokinetic data useful for understanding human metabolism of the compound.

BAM15 development priorities include improved formulations addressing the short half-life and low aqueous solubility. The nanoparticle delivery approach for targeted liver effects represents one promising direction. Human safety and tolerability studies, if confirmed to be underway, would represent a significant advance in characterizing the compound’s clinical potential.

Key Research Findings

SLU-PP-332 in Diet-Induced Obese Mice

Research Focus: Effects of 28-day SLU-PP-332 treatment on body composition, substrate utilization, and liver fat in diet-induced obese C57BL/6J mice Key Results: Animals receiving 50 mg/kg twice daily gained ten times less fat than controls, lost 12% of starting body weight, increased fatty acid oxidation by 25%, reduced respiratory exchange ratio indicating fuel source shift toward fat, elevated resting energy expenditure, and showed alleviation of hepatic steatosis; food intake and lean mass remained unchanged; adipocyte size and brown adipose tissue mass were unaffected Significance: Demonstrates that ERR activation can produce substantial fat reduction through metabolic reprogramming without appetite suppression or lean mass loss, distinguishing SLU-PP-332’s mechanism from weight loss interventions that reduce caloric intake Limitations: Single mouse strain at thermoneutrality; 28-day protocol only; no long-term data; results cannot be extrapolated to humans [pmc.ncbi.nlm.nih.gov/articles/PMC10801787/]

SLU-PP-332 Endurance Enhancement Study

Research Focus: Exercise capacity in normal-weight mice treated with SLU-PP-332 Key Results: Treated mice ran 70% longer and traveled 45% farther than untreated controls; oxidative muscle fiber profile shifted toward greater aerobic capacity; no changes in food intake Significance: Provides direct functional evidence for SLU-PP-332’s exercise-mimicking classification; the magnitude of endurance improvement explains WADA’s decision to prohibit the compound in competitive sports Limitations: Normal-weight mouse model may not translate to disease states; mechanisms underlying performance improvement require further characterization in human muscle physiology [news.ufl.edu/2023/09/exercise-mimicking-drug/]

SLU-PP-332 Cardiac Effects

Research Focus: Cardiac function in heart failure animal models treated with ERR agonists Key Results: Improved cardiac contractility, reduced apoptosis in cardiac cells, reduced fibrosis in treated animals; findings consistent with ERRalpha’s role as a master regulator of mitochondrial function in high-energy cardiac tissue Significance: Extends SLU-PP-332’s research profile beyond skeletal muscle and adipose tissue to cardiac applications; heart failure represents a major unmet need where mitochondrial dysfunction is a key disease feature Limitations: Heart failure model specifics and treatment duration not fully detailed in available sources; human cardiac ERR pathway response not characterized [pmc.ncbi.nlm.nih.gov/articles/PMC10399613/]

SLU-PP-332 Metabolite Profiling for Anti-Doping Detection

Research Focus: Characterization of SLU-PP-332 metabolites in human liver S9 fractions and microsomes for anti-doping purposes Key Results: Nine metabolites identified, six Phase-I oxidative and three Phase-II conjugates; detection accomplished using LC-HRMS/MS methodology; metabolite profiles sufficient to build detection assays for biological samples Significance: Establishes the human metabolic pathway for SLU-PP-332 and enables reliable detection in anti-doping testing; indirectly confirms the compound is metabolized through human hepatic pathways, providing some pharmacokinetic context Limitations: In vitro liver microsome data; actual in vivo human pharmacokinetics not yet characterized [pmc.ncbi.nlm.nih.gov/articles/PMC12835572/]

BAM15 Obesity Reversal Study

Research Focus: Effects of BAM15 on established diet-induced obesity in mouse models Key Results: Reversed diet-induced obesity; decreased body fat mass and hepatic fat content; reduced inflammatory lipids; improved insulin resistance across liver, muscle, and adipose tissue; 51% higher palmitate oxidation in liver; 49% reduction in 4-hydroxynonenal (lipid peroxidation marker); elevated glutathione; no body temperature changes; no lean mass loss; no blood marker abnormalities Significance: Demonstrates that safe mitochondrial uncoupling is achievable at the preclinical level, with multi-system metabolic benefits and a favorable safety profile compared to the historical DNP precedent Limitations: Mouse model only; oral bioavailability confirmed but short half-life of 1.7 hours limits sustained exposure without repeated dosing; no human data [pmc.ncbi.nlm.nih.gov/articles/PMC7224297/]

BAM15@BSA Nanoparticle Liver Targeting

Research Focus: Development and testing of albumin nanoparticle delivery system for liver-targeted BAM15 delivery in NAFLD models Key Results: Successful liver-targeted delivery demonstrated with nanoparticle formulation; organ-specific effects on hepatic lipid metabolism achieved at lower systemic doses than conventional administration Significance: Addresses BAM15’s formulation challenges directly; liver-targeted delivery reduces off-target exposure while maintaining therapeutic effects in the organ most relevant to NAFLD treatment Limitations: Early-stage delivery research; clinical translation of nanoparticle systems requires extensive additional development [pmc.ncbi.nlm.nih.gov/articles/PMC10600450/]

BAM15 in Septic Acute Kidney Injury

Research Focus: BAM15 effects on kidney tissue in septic acute kidney injury models Key Results: BAM15 activated AMPK in early septic AKI; protective effects on kidney tissue under acute inflammatory and metabolic stress Significance: Expands BAM15’s research profile beyond metabolic obesity to acute organ protection; AMPK activation in kidney tissue under septic conditions may represent a distinct therapeutic mechanism Limitations: Septic AKI model is distinct from metabolic disease applications; whether BAM15 reaches effective concentrations in kidney tissue during systemic sepsis requires further characterization [pubmed.ncbi.nlm.nih.gov/37900126/]

Frequently Asked Questions

What is SLU-PP-332?

SLU-PP-332 is a synthetic compound developed at Saint Louis University that activates estrogen-related receptors in cells. Researchers describe it as an exercise mimetic because it triggers some of the same cellular changes that occur during endurance training, particularly in muscle and heart tissue. All research to date has been conducted in animal models and cell cultures, with no human clinical trials completed.

What does BAM15 do?

BAM15 is a compound that works inside mitochondria, the energy-producing structures in cells, to increase the rate at which cells burn fuel. It does this by creating a proton leak in the mitochondrial membrane, forcing cells to oxidize more fat and glucose to maintain their energy supply. It was developed as a safer alternative to older compounds like DNP that worked through the same mechanism but caused dangerous side effects. Preclinical mouse studies showed it reversed diet-induced obesity and improved insulin resistance without raising body temperature.

Is SLU-PP-332 banned in sports?

Yes. WADA has placed SLU-PP-332 on its Prohibited List under Category S4: Hormone and Metabolic Modulators. The ban reflects the compound’s demonstrated ability to improve endurance metrics and shift metabolism in animal studies without physical training. Any competitive athlete subject to anti-doping testing who tests positive for SLU-PP-332 or its metabolites would face a doping violation.

Are SLU-PP-332 and BAM15 safe for humans?

Neither compound has established human safety data from controlled clinical trials. Both are classified for research use only and are not approved for human consumption. While animal studies did not identify serious adverse effects at tested doses, mouse physiology differs substantially from human physiology, and these results cannot be used to predict human safety. BAM15 belongs to a class of compounds that includes DNP, which was historically dangerous in humans, though BAM15 was specifically developed to address those toxicity concerns. All available safety information is preclinical only.

How long have SLU-PP-332 and BAM15 been studied?

SLU-PP-332 research began emerging in peer-reviewed literature around 2022 to 2023, with key preclinical publications from Saint Louis University and the University of Florida appearing through 2024. BAM15 obesity research appeared in major publications around 2020. Both compounds are relatively recent additions to the metabolic research landscape compared to compounds with decades of study history. The combination of these two compounds has been discussed primarily in non-peer-reviewed settings with no published controlled studies as of 2024. Researchers interested in the broader landscape of metabolic peptide research can explore additional compounds through the Cenexa Labs peptide research library.

References

1. SLU-PP-332 ERR agonist metabolic effects in diet-induced obese mice, 28-day treatment protocol. pmc.ncbi.nlm.nih.gov/articles/PMC10801787/

2. BAM15 obesity reversal, palmitate oxidation, insulin resistance, and oxidative stress findings in diet-induced obesity mouse model. pmc.ncbi.nlm.nih.gov/articles/PMC7224297/

3. BAM15@BSA nanoparticle delivery system for liver-targeted NAFLD treatment. pmc.ncbi.nlm.nih.gov/articles/PMC10600450/

4. ERR agonist cardiac contractility and fibrosis findings in heart failure models. pmc.ncbi.nlm.nih.gov/articles/PMC10399613/

5. SLU-PP-332 metabolite profiling via LC-HRMS/MS in human liver S9 and microsomes for anti-doping detection. pmc.ncbi.nlm.nih.gov/articles/PMC12835572/

6. SLU-PP-332 pan-ERR agonist pharmacology and exercise-mimetic activity. pubmed.ncbi.nlm.nih.gov/41421047/

7. ERR agonist mechanism of action and metabolic pathway studies. pubmed.ncbi.nlm.nih.gov/37739806/

8. SLU-PP-332 metabolite characterization and pharmacokinetic studies. pubmed.ncbi.nlm.nih.gov/41588687/

9. BAM15 AMPK activation in early septic acute kidney injury models. pubmed.ncbi.nlm.nih.gov/37900126/

10. University of Florida news coverage of SLU-PP-332 endurance enhancement preclinical research, 2023. news.ufl.edu/2023/09/exercise-mimicking-drug/